Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | EPRS1 | P07814 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17041239 | 0.85 | ALDH1A1 (0.41) | HSD17B10TDP1MAPTLCKFYN | |
| SCHEMBL979782 | 0.85 | HSD17B10 (0.51) | HSD17B10TDP1MAPTLCKFYN | |
| SCHEMBL6215179 | 0.85 | HSD17B10 (0.55) | HSD17B10TDP1MAPTLCKFYN | |
| SCHEMBL6535286 | 0.84 | KDM4E (0.41) | HSD17B10TDP1MAPTALDH1A1HPGD | |
| SCHEMBL6930173 | 0.81 | HSD17B10 (0.51) | HSD17B10TDP1MAPTLCKFYN | |
| SCHEMBL22245019 | 0.81 | TDP1 (0.56) | HSD17B10TDP1MAPTLCKFYN | |
| SCHEMBL1919502 | 0.81 | TDP1 (0.50) | HSD17B10TDP1MAPTALDH1A1HPGD | |
| SCHEMBL30316357 | 0.80 | HSD17B10 (0.50) | HSD17B10TDP1MAPTLCKFYN | |
| Ethane SCHEMBL6908717 | 0.80 | HSD17B10 (0.49) | HSD17B10MAPTALDH1A1HPGDKDM4E | |
| SCHEMBL1505827 | 0.80 | TDP1 (0.61) | HSD17B10TDP1MAPTLCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516479-B1 | NEW INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS | BASF CORP (US) | 2016-04-20 | — | — | EP | claimed |
| EP-2516479-A2 | NEW INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS | BASF Corporation (US) | 2012-10-31 | — | — | EP | claimed |
| US-8211819-B2 | Internal and external donor compounds for olefin polymerization catalysts | BASF CORPORATION (US) | 2012-07-03 | — | — | US | claimed |
| WO-2011084691-A2 | NEW INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS | BASF CORPORATION (US) | 2011-07-14 | — | — | WO | claimed |
| US-20110152481-A1 | Internal and external donor compounds for olefin polymerization catalysts | BASF CATALYSTS LLC (US) | 2011-06-23 | — | — | US | claimed |
| EP-3321268-B1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2025-06-04 | — | — | EP | disclosed |
| US-11040978-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-06-22 | — | — | US | disclosed |
| EP-3666758-A1 | PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE | AbbVie Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20190315755-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2019-10-17 | — | — | US | disclosed |
| US-20190211020-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-07-11 | — | — | US | disclosed |
| US-10280168-B2 | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-05-07 | — | — | US | disclosed |
| US-20180208600-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-07-26 | — | — | US | disclosed |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100152183-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010065865-A2 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-10 | — | — | WO | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| EP-1819684-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20060241121-A1 | Substituted piperazines as CB1 antagonists | MERCK SHARP & DOHME CORP. | 2006-10-26 | — | — | US | disclosed |
| WO-2006060461-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | SCHERING CORPORATION (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280168-B2 | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof | MAPKAPK2, NEK2, MKNK2 | HSD17B10 2645/4885TDP1 1264/4885MAPT 674/4885 |
| US-20190315755-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, MKNK2, MAP4K2 | HSD17B10 3850/4885TDP1 1034/4885MAPT 525/4885 |
| US-20100152183-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | HSD17B10 2707/4885TDP1 3300/4885MAPT 3942/4885 |
| US-20060241121-A1 | Substituted piperazines as CB1 antagonists | CNR1, CNR2, GPR119 | HSD17B10 1793/4885TDP1 4635/4885MAPT 1481/4885 |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | HSD17B10 1793/4885TDP1 4635/4885MAPT 1481/4885 |
| US-20190211020-A1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, NEK2, MKNK2 | HSD17B10 2656/4885TDP1 1277/4885MAPT 680/4885 |
| US-20180208600-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | MAPKAPK2, MKNK2, MAP4K2 | HSD17B10 3850/4885TDP1 1034/4885MAPT 525/4885 |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | HSD17B10 2707/4885TDP1 3300/4885MAPT 3942/4885 |
| US-11040978-B2 | Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof | MKNK2, MKNK1, MAPKAPK2 | HSD17B10 2941/4885TDP1 979/4885MAPT 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.